258 related articles for article (PubMed ID: 16201973)
1. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
Miyake H; Hara I; Gleave ME
Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
3. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
4. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Hara I; Kamidono S; Gleave ME
Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526
[TBL] [Abstract][Full Text] [Related]
5. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer.
Gleave M; Miyake H; Chi K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():47-57. PubMed ID: 16273354
[TBL] [Abstract][Full Text] [Related]
6. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 Jan; 60(1):170-6. PubMed ID: 10646870
[TBL] [Abstract][Full Text] [Related]
7. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
[TBL] [Abstract][Full Text] [Related]
8. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers.
Gleave M; Chi KN
Ann N Y Acad Sci; 2005 Nov; 1058():1-15. PubMed ID: 16394121
[TBL] [Abstract][Full Text] [Related]
9. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
Yamanaka K; Gleave M; Muramaki M; Hara I; Miyake H
Oncol Rep; 2005 May; 13(5):885-90. PubMed ID: 15809754
[TBL] [Abstract][Full Text] [Related]
10. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
Gleave M; Miyake H
World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
[TBL] [Abstract][Full Text] [Related]
11. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
Miyake H; Hara I; Fujisawa M; Gleave ME
Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
[TBL] [Abstract][Full Text] [Related]
12. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
13. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro.
Rocchi P; Jugpal P; So A; Sinneman S; Ettinger S; Fazli L; Nelson C; Gleave M
BJU Int; 2006 Nov; 98(5):1082-9. PubMed ID: 16879439
[TBL] [Abstract][Full Text] [Related]
14. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
Miyake H; Tolcher A; Gleave ME
Cancer Res; 1999 Aug; 59(16):4030-4. PubMed ID: 10463603
[TBL] [Abstract][Full Text] [Related]
15. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Yamanaka K; Muramaki M; Hara I; Gleave ME
Neoplasia; 2005 Feb; 7(2):171-9. PubMed ID: 15802022
[TBL] [Abstract][Full Text] [Related]
17. [Short-term neoadjuvant hormone therapy enhanced expression of clusterin in prostate cancer].
Niu YN; Xin DQ; He ZS; Zhou LQ; Pan BN; Na YQ; Guo YL
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):394-7. PubMed ID: 15854351
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.
Yamanaka K; Gleave ME; Hara I; Muramaki M; Miyake H
Mol Cancer Ther; 2005 Feb; 4(2):187-95. PubMed ID: 15713890
[TBL] [Abstract][Full Text] [Related]
19. Clusterin is not essential for androgen-regulated involution and regeneration of the normal mouse prostate.
Fink D; Fazli L; Aronow B; Gleave ME; Ong CJ
Prostate; 2006 Sep; 66(13):1445-54. PubMed ID: 16865725
[TBL] [Abstract][Full Text] [Related]
20. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
